Last reviewed · How we verify
Vitamin K antagonists (VKA)
Vitamin K antagonists inhibit the vitamin K-dependent gamma-carboxylation of clotting factors, leading to anticoagulation.
Vitamin K antagonists inhibit the vitamin K-dependent gamma-carboxylation of clotting factors, leading to anticoagulation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis and pulmonary embolism prevention.
At a glance
| Generic name | Vitamin K antagonists (VKA) |
|---|---|
| Also known as | Warfarin |
| Sponsor | Population Health Research Institute |
| Drug class | Vitamin K antagonist |
| Target | VKORC1 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This mechanism is achieved by blocking the action of vitamin K epoxide reductase complex 1 (VKORC1), which is necessary for the gamma-carboxylation of clotting factors II, VII, IX, and X. As a result, these clotting factors are not activated, and blood clotting is inhibited.
Approved indications
- Atrial fibrillation for stroke prevention
- Deep vein thrombosis and pulmonary embolism prevention
Common side effects
- Bleeding
- Bruising
- Nosebleeds
Key clinical trials
- SIMPLAAFY Clinical Trial (NA)
- Anticoagulation in Patients With Venous Thromboembolism and Cancer
- High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
- Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus (PHASE3)
- Effect of Telitacicept on Antibody Titers in Primary APS Patients (PHASE2)
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PHASE3)
- Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
- The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vitamin K antagonists (VKA) CI brief — competitive landscape report
- Vitamin K antagonists (VKA) updates RSS · CI watch RSS
- Population Health Research Institute portfolio CI